QCG
CHRS icon

Quadrant Capital Group’s Coherus Oncology CHRS Stock Holding History

Quadrant Capital Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-457
Closed -$1.52K – 2727
2023
Q4 		$1.52K Buy
+457
New +$1.22K ﹤0.01% 2514
2023
Q1 		– Sell
-21
Closed -$166 – 2729
2022
Q4 		$166 Hold
21
– – ﹤0.01% 2705
2022
Q3 		$0 Hold
21
– – ﹤0.01% 2650
2022
Q2 		$0 Buy
21
+9
+75% +$78 ﹤0.01% 2559
2022
Q1 		$0 Sell
12
-16
-57% -$203 ﹤0.01% 2516
2021
Q4 		$0 Hold
28
– – ﹤0.01% 2533
2021
Q3 		$0 Buy
28
+10
+56% +$147 ﹤0.01% 2524
2021
Q2 		$0 Sell
18
-8
-31% -$113 ﹤0.01% 2427
2021
Q1 		$0 Buy
+26
New +$441 ﹤0.01% 2388

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Quadrant Capital Group's CHRS Position: Q1 2024 in Review

Quadrant Capital Group sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 457 shares — an estimated $1.52K sold.

Quadrant Capital Group first reported a position in CHRS in Q1 2021 and held it in 9 quarters. The position peaked at $1.52K in Q4 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Quadrant Capital Group reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 457 Coherus Oncology shares in Q1 2024, an estimated $1.52K.
  • Quadrant Capital Group first reported a position in Coherus Oncology in Q1 2021 and held it in 9 quarters.
  • Quadrant Capital Group's Coherus Oncology position peaked at $1.52K in Q4 2023.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Quadrant Capital Group's 13F filing for Q1 2024, filed 15 May 2024.